# Neuphoria Therapeutics Inc.: overview

NEUP · Nasdaq · CIK 1191070 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/neup.md) · [Financials](/companies/neup/financials.md) · [Filings](/companies/neup/filings.md) · [Insiders](/companies/neup/insiders.md)

Latest reported revenue: [−$13.3k](/filings/0001193125-25-223338.md) for Q4 FY2025, three months to 2025-06-30, from the 10-K filed Sep 29, 2025 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-25-223338).

## Last eight quarters

| Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | [0.7](/filings/0001193125-26-054509.md) | [15.0](/filings/0001193125-26-225442.md) | [(0.0) d](/filings/0001193125-25-223338.md) | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | [(558.8%)](/filings/0001193125-26-054509.md) | [79.8%](/filings/0001193125-26-225442.md) | [43981.7% d](/filings/0001193125-26-395536.md) | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | [(293.2%)](/filings/0001193125-26-225442.md) | [75.1%](/filings/0001193125-26-225442.md) | [66960.6% d](/filings/0001193125-26-395536.md) | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.62)](/filings/0001193125-25-281579.md) | [(1.79)](/filings/0001193125-26-054509.md) | [6.55](/filings/0001193125-26-225442.md) | not reported | [(4.41)](/filings/0001193125-25-281579.md) | [(0.77)](/filings/0001193125-26-054509.md) | [(0.09)](/filings/0001193125-26-225442.md) | not reported |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.

## Last five fiscal years

| Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.3](/filings/0000950170-23-053873.md) | [0.0](/filings/0000950170-23-053873.md) | not reported | [15.6](/filings/0001193125-25-223338.md) | [1.2](/filings/0001193125-26-395536.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | [(99709.6%)](/filings/0001213900-24-082909.md) | not reported | [(7.2%)](/filings/0001193125-26-395536.md) | [(1401.1%)](/filings/0001193125-26-395536.md) |
| Net margin | % | [346.5%](/filings/0000950170-22-019563.md) | [(96982.3%)](/filings/0001213900-24-082909.md) | not reported | [(2.4%)](/filings/0001193125-26-395536.md) | [(1145.7%)](/filings/0001193125-26-395536.md) |
| Diluted EPS | $ per share | [(0.02)](/filings/0000950170-23-053873.md) | [(0.02)](/filings/0001213900-24-082909.md) | [(18.62)](/filings/0001193125-25-223338.md) | [(0.23)](/filings/0001193125-26-395536.md) | [(3.06)](/filings/0001193125-26-395536.md) |
| Free cash flow | $m | [(21.8)](/filings/0000950170-23-053873.md) | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: ifrs-full:Revenue; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: ifrs-full:Revenue; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Revenue: ifrs-full:Revenue; Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:Revenue; Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare; Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/neup/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Lynx1 Capital Management LP](/funds/1910456.md) | 2026-06-30 | $3.8m | 875,328 |  | Unchanged |
| [AdvisorShares Investments LLC](/funds/1425930.md) | 2026-06-30 | $1.1m | 252,909 |  | Added +97,542 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $758.1k | 173,488 |  | Added +74,972 |
| [Shay Capital LLC](/funds/1723643.md) | 2026-06-30 | $680.9k | 155,822 |  | Added +4,812 |
| [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $621.5k | 142,228 |  | Added +45 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $317.1k | 72,559 |  | Added +53,228 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $216.4k | 49,516 |  | Reduced −2,491 |
| [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $207.3k | 47,443 |  | Unchanged |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $147.7k | 33,806 |  | Added +217 |
| [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $131.1k | 30,000 |  | Unchanged |

## Recent filings

[All 219 filings](/companies/neup/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-23 | 08:00 ET | [8-K](/filings/0001213900-26-111863.md) | 1.01 Entry into a material agreement; 3.03 Change to security holders’ rights; 9.01 Financial statements and exhibits | 0001213900-26-111863 |
| 2026-09-18 | 20:33 ET | [DEF 14A](/filings/0001140361-26-037139.md) | Proxy statement, period 2026-11-02 | 0001140361-26-037139 |
| 2026-09-18 | 20:10 ET | [10-K](/filings/0001193125-26-395536.md) | Annual report, period 2026-06-30 | 0001193125-26-395536 |
| 2026-07-24 | 22:37 ET | [8-K](/filings/0001213900-26-081052.md) | 1.01 Entry into a material agreement; 5.01 Change in control; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-081052 |
| 2026-05-26 | 20:15 ET | [8-K](/filings/0001213900-26-061028.md) | 8.01 Other events | 0001213900-26-061028 |
| 2026-05-15 | 12:33 ET | [10-Q](/filings/0001193125-26-225442.md) | Quarterly report, period 2026-03-31 | 0001193125-26-225442 |
| 2026-02-17 | 20:57 ET | [10-Q](/filings/0001193125-26-054509.md) | Quarterly report, period 2025-12-31 | 0001193125-26-054509 |
| 2026-01-08 | 22:48 ET | [8-K](/filings/0001213900-26-002245.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-002245 |
| 2025-12-29 | 21:33 ET | [SCHEDULE 13D/A](/filings/0000905148-25-004490.md) | Ownership report, active investor, amended | 0000905148-25-004490 |
| 2025-12-18 | 21:15 ET | [8-K](/filings/0001213900-25-123289.md) | 3.01 Delisting notice | 0001213900-25-123289 |

## Latest annual report

[Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001193125-26-395536.md), filed Sep 18, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1191070
- Tickers: NEUP
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: C3
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.